Prognostic factors for head and neck tumor recurrence

The introduction of new treatment methods has stimulated the identification of further prognostic factors capable of defining the clinical and biological characteristics of the tumor type in question and improving treatment programming. The aim of this study was to identify which characteristics of...

Full description

Saved in:
Bibliographic Details
Published inActa oto-laryngologica Vol. 115; no. 6; p. 833
Main Authors Magnano, M, Bussi, M, De Stefani, A, Milan, F, Lerda, W, Ferrero, V, Gervasio, F, Ragona, R, Gabriele, P, Valente, G
Format Journal Article
LanguageEnglish
Published England 1995
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:The introduction of new treatment methods has stimulated the identification of further prognostic factors capable of defining the clinical and biological characteristics of the tumor type in question and improving treatment programming. The aim of this study was to identify which characteristics of the host and tumor are of prognostic value in relation to the onset of locoregional tumor recurrence. A total of 396 patients were studied. The tumor site distribution can be summarized as follows: 267 laryngohypopharyngeal, 74 oropharyngeal, 55 oral cavity. Variables regarding patient, tumor and histology were evaluated for the purpose of analysis. Multivariate analysis of these prognostic factors was performed using PLR software by BMDP. Mean tumor recurrence time was 19 months. Seventeen of the 29 variables analysed did not influence the probability of tumor recurrence. Two variables reduced the risk of tumor recurrence: age > 61 years and abundant and prevalently lymphocytic intra-and peritumoral infiltrate. The study of tumor recurrence onset mechanisms is justified by its impact on the evolution of disease. The use of multivariate analysis in this study showed that some clinical and pathological characteristics of squamous cell carcinoma of the head and neck have a statistically significant impact on tumor recurrence.
ISSN:0001-6489
1651-2251
DOI:10.3109/00016489509139410